Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists - 30/09/19
, Flavio Bosshard a, Michael Nagler c, Beat Roth d, Aristomenis K. Exadaktylos a, Thomas C. Sauter a, e, ⁎Abstract |
Objective |
To investigate the influence of type of anticoagulation – direct oral anticoagulants (DOAC) vs vitamin K antagonists (VKA) – on length of hospital stay (LOS) and hospitalization rates in patients with visible hematuria, as visible hematuria in anticoagulated patients can be distressing, difficult to control and even life-threatening.
Methods |
This retrospective cohort study was conducted at the emergency department (ED) of a tertiary university hospital in Switzerland. All patients admitted with visible hematuria from January 1, 2013 to December 31, 2016 were included. We compared the primary clinical outcome parameters (hospitalization rate and LOS) as well as secondary outcomes (ICU admission, ED LOS, and in-hospital mortality) in patients with visible hematuria on either DOAC therapy, VKA therapy or no anticoagulants.
Results |
We included 811 (100%) patients with visible hematuria; 53 (6.5%) patients were on DOAC, compared to 85 (10.5%) on VKA and 673 (83.0%) patients without any anticoagulation. In confounder-adjusted multivariable testing, there were fewer hospitalizations (odds ratio: 2.2, 95% confidence interval [CI]: 1.1-4.9, P = .028) and shorter LOS (geometric mean ratio: 2.2, 95% CI: 1.3-4.0, P = .006) on DOAC than on VKA. The secondary outcomes were not significantly associated with the anticoagulation groups. No differences were found between the DOAC and no-anticoagulant groups for any outcome.
Conclusion |
Visible hematuria in patients on DOAC therapy is associated with shorter hospital stays and fewer hospitalizations compared to VKA.
Le texte complet de cet article est disponible en PDF.Plan
| Authorship contribution: MM and TCS designed the study, drafted the manuscript and performed statistical analyses of data. MN contributed to the study design and critically revised the manuscript. FB collected data, helped with the interpretation of data and critically revised the manuscript. AKE helped with the study design, helped with the interpretation of data and critically revised the manuscript. BR critically revised the manuscript and helped with the interpretation of data. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. |
|
| Conflict of interest: TCS has received research grants or lecture fees from Bayer, Boehringer Ingelheim, and Daiichi-Sankyo and Gottfried und Julia Bangerter-Rhyner-Foundation. MM has received research grants of Gottfried und Julia Bangerter-Rhyner-Foundation. MN has received research grants or lecture fees from Bayer, CSL Behring, Roche diagnostics, and Instrumentation Laboratory. AKE is member of the advisory boards of all registered DOACs. FB and BR report no conflict of interest. |
Vol 132
P. 101-108 - octobre 2019 Retour au numéro
Article précédent
- Evaluation of Implementation Outcomes After Initiation of a Shared Decision-making Program for Men With Prostate Cancer
- Adam Peña, Zhiyu Qian, Sylvia Lambrechts, John N. Cabri, Casey Weiser, Hui Liu, Lorna Kwan, Christopher S. Saigal
- Total Motile Sperm Count Trend Over Time: Evaluation of Semen Analyses From 119,972 Men From Subfertile Couples
- Ashley W. Tiegs, Jessica Landis, Nicolás Garrido, Richard T. Scott, James M. Hotaling
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?